Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $59000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 73.53% year-over-year to $59000.0, compared with a TTM value of $396000.0 through Sep 2025, up 175.0%, and an annual FY2024 reading of $169000.0, up 6.96% over the prior year.
  • Depreciation & Amortization (CF) was $59000.0 for Q3 2025 at Avalo Therapeutics, down from $134000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $456000.0 in Q2 2021 and bottomed at $30000.0 in Q2 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $130421.1, with a median of $43000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 93.42% in 2022, then surged 306.06% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $295000.0 in 2021, then tumbled by 88.14% to $35000.0 in 2022, then grew by 22.86% to $43000.0 in 2023, then skyrocketed by 58.14% to $68000.0 in 2024, then dropped by 13.24% to $59000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AVTX at $59000.0 in Q3 2025, $134000.0 in Q2 2025, and $135000.0 in Q1 2025.